Regorafenib for advanced gastrointestinal stromal tumors following imatinib and sunitinib treatment: a subgroup analysis evaluating Japanese patients in the phase III GRID trial
Crossref DOI link: https://doi.org/10.1007/s10147-015-0790-y
Published Online: 2015-02-06
Published Print: 2015-10
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Komatsu, Yoshito
Doi, Toshihiko
Sawaki, Akira
Kanda, Tatsuo
Yamada, Yasuhide
Kuss, Iris
Demetri, George D.
Nishida, Toshirou
Text and Data Mining valid from 2015-02-06